J.Safra Asset Management Corp Grows Position in argenx SE (NASDAQ:ARGX)

J.Safra Asset Management Corp lifted its holdings in shares of argenx SE (NASDAQ:ARGX) by 123.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 273 shares of the company’s stock after buying an additional 151 shares during the period. J.Safra Asset Management Corp’s holdings in argenx were worth $169,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Steward Partners Investment Advisory LLC boosted its position in shares of argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after buying an additional 20 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after buying an additional 21 shares during the last quarter. Dynasty Wealth Management LLC boosted its position in shares of argenx by 3.4% during the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after buying an additional 22 shares during the last quarter. Choreo LLC boosted its position in shares of argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after buying an additional 23 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in shares of argenx by 4.2% during the fourth quarter. IFP Advisors Inc now owns 641 shares of the company’s stock valued at $394,000 after buying an additional 26 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on ARGX shares. Deutsche Bank Aktiengesellschaft cut argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Truist Financial reissued a “buy” rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Robert W. Baird raised their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday. Oppenheimer raised their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, HC Wainwright raised their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $662.83.

argenx Price Performance

NASDAQ:ARGX opened at $636.49 on Thursday. The company has a market cap of $38.67 billion, a price-to-earnings ratio of -723.28 and a beta of 0.58. The stock’s 50 day simple moving average is $642.34 and its two-hundred day simple moving average is $592.58. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, analysts anticipate that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.